Stakeholders engaged in this domain are presently focusing on introducing advanced features, such as integrated continuous glucose monitoring (CGM) systems, artificial intelligence (AI) enabled algorithms, provisions for audiovisual / tactile feedback, and automatic drug reconstitution features. Such efforts are primarily directed towards differentiating proprietary offerings within a highlight competitive market landscape, and are expected to drive the market’s growth over the coming years.

To order this 240+ page report, which features 50+ figures and 70+ tables, please visit this link

The USD 31 million (by 2030) financial opportunity within the diabetes drug delivery devices market has been analyzed across the following segments:
 Type of Device
 Pen-Injectors
 Insulin Pumps
 Conventional Syringes
 Others

 Route of Administration
 Subcutaneous
 Intravenous
 Others

 Type of Diabetes
 Type 1
 Type 2

 Usability of the Device
 Disposable
 Reusable

 Key Geographies
 North America
 Europe
 Asia Pacific
 Rest of the World

The Diabetes Drug Delivery Devices Market, 2020-2030 report features the following companies, which we identified to be key players in this domain:
 Bigfoot Biomedical
 Debiotech
 Haselmeier
 Medtronic
 Novo Nordisk
 Roche
 SOOIL
 Ypsomed

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Current Market Landscape

5. Product Competitive Analysis

6. Partnerships and Collaborations

7. Company Profiles

8. Diabetes Drug Delivery Devices Related Initiatives of Big Pharma Players

9. Market Sizing and Opportunity Analysis

10. Concluding Remarks

11. Executive Insights

12. Appendix 1: Tabulated Data

13. Appendix 2: List of Companies and Organizations

To purchase a copy, please visit https://www.rootsanalysis.com/reports/diabetes-drug-delivery-device...

Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]